The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1650
ISSUE 1650
May 16, 2022
Issue 1650
- A Three-Antigen Hepatitis B Vaccine (PreHevbrio)
- Tretinoin/Benzoyl Peroxide Cream (Twyneo) for Acne
- Delayed-Release Budesonide (Tarpeyo) for Primary Immunoglobulin A Nephropathy
- In Brief: OTC Alcaftadine (Lastacaft Once Daily Relief) for Allergic Conjunctivitis
- In Brief: Higher-Dose Semaglutide (Ozempic) for Type 2 Diabetes
- Addendum: Dexlansoprazole for GERD
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
A Three-Antigen Hepatitis B Vaccine (PreHevbrio)
May 16, 2022 (Issue: 1650)
The FDA has licensed PreHevbrio (VBI Vaccines), a
recombinant, 3-antigen, 3-dose hepatitis B vaccine,
for the prevention of infection caused by all known
subtypes of hepatitis B virus (HBV) in adults. It has
been available in Israel since...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.